Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Covidien has received the US Food and Drug Administration (FDA) approval for its Mallinckrodt business for morphine sulfate oral solution.
Subscribe to our email newsletter
The solution, which will be launched as a generic in 100 milligrams per 5ml (20 milligrams per 1 ml), is intended to relieve moderate to severe acute and chronic pain in opioid-tolerant patients.
Covidien Pharmaceuticals interim president and chief financial officer Matthew Harbaugh said FDA approval of this drug represents a key component in palliative care treatment.
"It is important that we are able to respond to the concerns of the hospice and palliative care community," Harbaugh said.